[en] Nonalcoholic steatohepatitis (NASH), along with other forms of nonalcoholic fatty liver disease, is an increasingly common clinico-pathological syndrome. It is frequently associated with obesity, especially visceral fat, and type 2 diabetes, and is intimately related to markers of the insulin resistance syndrome. Both the prevalence and the severity of liver steatosis are related to body mass index, waist circumference, hyperinsulinaemia, hypertriglyceridemia and impaired glucose tolerance. The pathophysiology of NASH involves two steps: 1) insulin resistance, which causes steatosis; 2) and oxidative stress, which produces lipid peroxidation and activates inflammatory cytokines. The identification of subjects who may progress from fatty liver to NASH, and from NASH to fibrosis/cirrhosis is an important clinical challenge as well as the finding of appropriate therapy that could prevent such deleterious process. Substantial weight loss is accompanied by a marked attenuation of insulin resistance and related metabolic syndrome and, concomitantly, by an important regression of liver steatosis in most patients, although mild inflammation may be detected in some subjects. Thus, NASH may be considered as another disease of affluence, as is the insulin resistance syndrome and perhaps being part of it.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Luyckx, Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Language :
English
Title :
Nonalcoholic steatohepatitis and insulin resistance: interface between gastroenterologists and endocrinologists.
Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going ? Dig Dis 1999; 17: 80-9.
Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002; 34: 255-62.
Ludwig J, Viggiano TR, McGill DB, Ott B. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
Luyckx FH, Lefèbvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000; 26: 98-106.
Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 2002: 16: 703-16.
James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999; 353: 1634-6
Guzzaloni G, Grugni G, Minocci A, Moro D, Morabito F. Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. Int J Obesity 2000; 24: 772-6.
Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-43.
Garcia Monzon C, Martin-Perez E, Iacono OL et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33: 716-24.
Sanyal AJ, Campbell-Sargent C, Mirshani F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
Day CP, James OFW. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-5.
Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997, 45, 3-10.
Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int J Obesity 1995; 19 (Suppl 3): S27-S36.
Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998; 27: 1463-6.
Zimmerman HJ, MacMurray FG, Rappaport H, Alpert IK. Studies of the liver in diabetes mellitus. II. The significance of fatty metamorphosis and its correlation with insulin insensitivity. J Lab Clin Med 1950; 36: 922-7.
Belfiore F, Iannello S. Insulin resistance in obesity: metabolic mechanisms and measurement methods. Mol Genet Metab 1998; 65: 121-8.
Scheen AJ, Luyckx FH. Medical aspects of obesity. Acta Chir Belg 1999; 99: 135-9.
Meek SE, Nair KS, Jensen MD. Insulin regulation of regional free fatty acid metabolism. Diabetes 1999; 48: 10-4.
Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest 1986; 78: 1648-57.
Goto T, Onuma T, Takebe K, Kral JG. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obesity 1995; 19: 841-5.
Scheen AJ. Lessons from the discovery of leptin: is obesity an endocrine disease? Acta Clin Belg 1996; 51: 371-6.
Tobe K, Ogura T, Tsukamoto C et al. Relationship between serum leptin and fatty liver in Japanese male adolescent university students. Am J Gastroenterol 1999; 94: 3328-35.
Uygun A, Kadayifci A, Yesilova Z et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95: 3584-9.
Lee Y, Wang MY, Kakuma T et al. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem 2001; 276: 5629-35.
Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762-71.
Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.
Hotamisligil GH, Spiegelman BM. Tumor necrosis factor alpha. A key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-8.
Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
Wigg AJ, Roberts-Thomson IC, Dymock RB et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia and tumour necrosis alpha in the pathogenesis of nonalcoholic steatohepatitis. Gut 2001; 48: 206-11.
Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diabetes Rep 2002; 2: 210-5.
Yang S, Zhu H, Li YB et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000; 378: 259-68.
Macdonald GA & Powell LW. More clues to the relationship between hepatic iron and steatosis. An association with insulin resistance ? Gastroenterology 1999; 117: 1241-4.
Ferrannini E. Insulin resistance, iron, and the liver. Lancet 2000; 355: 2181-2.
George DK, Goldwurm S, MacDonald GA et al. Increased hepatic iron concentration in nonalcoholic steatothepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-8.
Andersen T, Gluud C. Liver morphology in morbid obesity: a literature survey. Int J Obesity 1984; 8: 97-106.
Marceau P, Biron S, Hould FS et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-7.
Luyckx FH, Desaire C, Thiry A et al. Liver abnormalities in severely obese subjects: effects of drastic weight loss after gastroplasty. Int J Obesity 1998; 22: 222-6.
Nagore N, Scheuer PJ. The pathology of diabetic hepatitis. J Pathol 1998; 156: 155-60.
Angulo P, Keach JC, Batts KP et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
Baig NA, Herrine SK, Rubin R. Liver disease and diabetes mellitus. Clin Lab Med 2001; 21: 193-207.
Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75: 473-86.
Scheen AJ. Insulin resistance syndrome and atherosclerotic cardiovascular disease. Acta Clin Belg 1996; 51: 65-9.
Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol 1999, 84 (Suppl 1A), 28J-32J.
Banerji MA, Buckley MC, Chaiken RL, Gordon G, Lebovitz HE, Kral JG. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obesity 1995; 19: 846-50.
Oehler G, Bleyl H, Matthes KJ. Hyperinsulinemia in hepatic steatosis. Int J Obesity 1982; 6 (Suppl 1): 137-44.
Marchesini G, Brizi M, Morselli-Labate AM et al. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
Comert B, Mas MR, Erdem H et al. Insulin resistance in nonalcoholic steatohepatitis. Dig Liver Dis 2001; 33: 353-8.
Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-72.
Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
Cortez-Pinto H, Camilo ME, Baptista A et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome ? Clin Nutr 1999; 18: 353-8.
Knobler H, Schattner A, Zhornicki T et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. Q J Med 1999; 92: 73-9.
Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994; 7: 761-811.
Després JP. The insulin resistance dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obesity Res 1998; 6 (Suppl 1): 8S-17S.
Kral J, Schaffner F, Pierson R, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993; 42: 548-51.
Lee JH, Rhee PL, Lee JK et al. Role of hyperinsulinemia and glucose intolerance in the pathogenesis of nonalcoholic fatty liver in patients with normal body weight. Korean J Intern Med 1998; 13: 12-14.
Barzilai N, Liu BQ, Vuguin P, Cohen P, Wang J, Rossetti L. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999; 48: 94-8.
Luyckx FH, Scheen AJ, Desaive C, Dewé W, Gielen JE, Lefèbvre PJ. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. Diabetes Metab 1998; 24: 355-61.
Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957-61.
Moirand R, Mortaji AM, Loréal O, Paillard F, Brissot P, Deugner Y. A new syndrome of liver overload with normal transferrin saturation. Lancet 1997; 349: 95-7.
Mendler MH, Turlin B, Moirand R et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1157-63.
Guillygomarc'h A, Mendler MH, Moirand R et al. Venesection therapy of insulin-resistance-associated hepatic iron overload. J Hepatol 2001; 35: 344-9.
Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-9.
Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21: 81-8.
Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatology 1997; 27: 103-7.
Fong DG, Nehra V, Lindor K, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000; 32: 3-10.
Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002; 35: 497-9.
Scheen AJ, Lefèbvre PJ. Management of the obese diabetic patient. Diabetes Rev 1999; 7: 77-93.
Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nature Med 2000; 6: 998-1003.
Marchesini G, Brizi M, Bianchi G et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-9.
Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-25.
Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect ? Drug Safety 2001; 24: 873-88.
Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials. Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-21.
Peters RL, Gay T, Reynolds TB. Post-jejunoileal bypass hepatic disease. Its similarity to alcoholic liver disease. Am J Clin Pathol 1975; 63: 318-31.
Vyberg M, Ravn V, Andersen B. Pattern of progression in liver injury following jejunoileal bypass for morbid obesity. Liver 1987; 7: 271-6.
Hocking MP, Davis GL, Franzini DA et al. Long-term consequences after jejunoileal bypass for morbid obesity. Dig Dis Sci 1998; 43: 2493-9.
Scheen AJ, Luyckx FH, Desaive C, Lefèbvre PJ. Severe/extreme obesity: a medical disease requiring a surgical treatment ? Acta Clin Belg 1999; 54: 154-61.
Letiexhe MR, Scheen AJ, Gérard PL, Desaive C, Lefèbvre PJ. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab 1995; 89: 393-9.
Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970; 282: 829-34.
Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995; 104: 23-31.
Luyckx FH, Scheen AJ, Desaive C, Thiry A, Lefèbvre PJ. Parallel reversibility of biological markers of the metabolic syndrome and liver steatosis after gastroplasty-induced weight loss in severe obesity (Letter). J Clin Endocrinol Metab 1999; 84: 4293.
